

10/089,553

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:18:07 ON 09 SEP 2003

=> file reg

=>

Uploading 10089553.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

L2 5 SEA SSS FUL L1

=> file ca

COST IN U.S. DOLLARS SINCE FILE TOTAL

=> s l2

L3 1 L2

=> d ibib abs hitstr

L3 ANSWER 1 OF 1 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 134:290390 CA

TITLE: Dihydroorotate dehydrogenase inhibitors, and use with other agents, for the treatment of virus-mediated diseases

INVENTOR(S): Tan, Yin Hwee; Driscoll, John Stanford; Mui Mui, Sim

PATENT ASSIGNEE(S): Institute of Molecular and Cell Biology, Singapore; Mui Mui, Sim

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024785	A2	20010412	WO 2000-US26797	20000929
WO 2001024785	A3	20020711		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1237546	A2	20020911	EP 2000-965517	20000929

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003510352 T2 20030318 JP 2001-527784 20000929

PRIORITY APPLN. INFO.: US 1999-157017P P 19991001

WO 2000-US26797 W 20000929

OTHER SOURCE(S): MARPAT 134:290390

AB Flavivirus, rhabdovirus, and paramyxovirus infections may be treated by administering an inhibitor of dihydroorotate dehydrogenase, e.g. 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt (Brequinar). A synergistic effect can be obtained if an interferon, e.g. interferon .alpha.2, interferon .alpha.8 or interferon .beta., or an inhibitor of a second enzyme selected from inosine monophosphate dehydrogenase, guanosine monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocysteine hydrolase, is also administered. Compd. prepn. is described.

IT 333969-73-6P 333969-74-7P 333969-75-8P


333969-76-9P 333969-77-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(dihydroorotate dehydrogenase inhibitors, and use with other agents, for the treatment of virus-mediated diseases)


RN 333969-73-6 CA

CN 4-Quinolinecarboxylic acid, 2-[1,1'-biphenyl]-4-yl-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 333969-74-7 CA


CN 4-Quinolinecarboxylic acid, 2-[1,1'-biphenyl]-4-yl-3-methyl-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 333969-75-8 CA


CN 4-Quinolinecarboxylic acid, 2-(4-cyclohexylphenyl)-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

10/089,553




RN 333969-76-9 CA

CN 4-Quinolinecarboxylic acid, 2-[2-methoxy-3-methyl-4-(phenylmethoxy)phenyl]-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 333969-77-0 CA

CN 4-Quinolinecarboxylic acid, 2-(4-phenoxyphenyl)-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



=> file marpat

=> s ll full

L4 2 SEA SSS FUL L1

=> d ibib abs fqhit 1-2

L4 ANSWER 1 OF 2 MARPAT COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 136:279353 MARPAT

TITLE: Antiparasitic compounds

INVENTOR(S): Jones, Keith; Whitfield, Philip John; Rossiter, Sharon; Matthewson, Michael Derek

PATENT ASSIGNEE(S): King's College London, UK

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026713	A1	20020404	WO 2001-GB4337	20010928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001092030	A5	20020408	AU 2001-92030	20010928
PRIORITY APPLN. INFO.:			GB 2000-23918	20000929
			WO 2001-GB4337	20010928

OTHER SOURCE(S): CASREACT 136:279353

AB Approx. 75 quinoline parasiticides were prepd. by cyclization of anilines with malonic acid to give quinolines and the subsequent derivatization of the quinolines. Thus, p-toluidine, malonic acid and POCl<sub>3</sub> were refluxed 5 h to give 51% 2,4-dichloro-6-methylquinoline (I), which was refluxed in methanolic NaOMe 40 h to give 84% 2,4-dimethoxy-6-methylquinoline. Ten of the quinoline derivs. were tested as anthelmintics and ecto-parasiticides against *Haemonchus contortus*, *Schistosoma mansoni* cercariae, *Caenorhabditis elegans*, *Lucilla cuprina*, and *Boophilus microplus*. E.g., the LD<sub>50</sub> for I against *C. elegans* after 60 min was 1.5 .mu.M.

## MSTR 1

G1 = 41 / CO<sub>2</sub>H / Ph (SO (1-) G10)

G2 = F  
 G7 = alkyl<(1-6)> (SO (1-3) G2)  
 G9 = N  
 G10 = aryl<(6-10)>  
 MPL: claim 1  
 NTE: also incorporates claims 59 and 60  
 NTE: or pharmaceutically acceptable salts, solvates or quaternary ammonium salts  
 NTE: substitution is restricted

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 MARPAT COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 134:290390 MARPAT


10/089,553

TITLE: Dihydroorotate dehydrogenase inhibitors, and use with other agents, for the treatment of virus-mediated diseases  
INVENTOR(S): Tan, Yin Hwee; Driscoll, John Stanford; Mui Mui, Sim  
PATENT ASSIGNEE(S): Institute of Molecular and Cell Biology, Singapore; Mui Mui, Sim  
SOURCE: PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024785	A2	20010412	WO 2000-US26797	20000929
WO 2001024785	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1237546	A2	20020911	EP 2000-965517	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003510352	T2	20030318	JP 2001-527784	20000929
PRIORITY APPLN. INFO.: US 1999-157017P 19991001				
WO 2000-US26797 20000929				


AB Flavivirus, rhabdovirus, and paramyxovirus infections may be treated by administering an inhibitor of dihydroorotate dehydrogenase, e.g. 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt (Brequinar). A synergistic effect can be obtained if an interferon, e.g. interferon .alpha.2, interferon .alpha.8 or interferon .beta., or an inhibitor of a second enzyme selected from inosine monophosphate dehydrogenase, guanosine monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocysteine hydrolase, is also administered. Compd. prepn. is described.

#### MSTR 1A




G1 = OCF3  
G4 = 11-9 14-22

10/089,553



G6 = cyclohexyl  
G10 = CO<sub>2</sub>H  
G12 = 91



MPL: claim 2

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 15:19:31 ON 09 SEP 2003

10/089,553

ACCESSION NUMBER: 137:88442 CA  
TITLE: Incensole and furanogermacrene and compounds in  
treatment for inhibiting neoplastic lesions and  
microorganisms  
INVENTOR(S): Shanahan-Pendergast, Elisabeth  
PATENT ASSIGNEE(S): Ire.  
SOURCE: PCT Int. Appl., 68 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		

W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD,  
UA, UG, US, VN, YU, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI,  
ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixt. showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.


IT 96201-88-6, Brequinar Sodium

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

RN 96201-88-6 CA

CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

IT 96201-88-6, Brequinar Sodium

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

10/089,553



10/089,553

ACCESSION NUMBER: 133:187987 CA  
TITLE: Methods using pyrimidine-based nucleosides for treatment of mitochondrial disorders  
INVENTOR(S): Naviaux, Robert K.  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050043	A1	20000831	WO 2000-US4663	20000223
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
NZ 513926	A	20010928	NZ 2000-513926	20000223
BR 2000008447	A	20020115	BR 2000-8447	20000223
EP 1171137	A1	20020116	EP 2000-910321	20000223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002537340	T2	20021105	JP 2000-600654	20000223
PRIORITY APPLN. INFO.:			US 1999-121588P P	19990223
			WO 2000-US4663 W	20000223

OTHER SOURCE(S): MARPAT 133:187987


AB Methods are provided for the treatment of mitochondrial disorders. The methods include the administration of a pyrimidine-based nucleoside, e.g. triacetyluridine. Also provided are methods of reducing or eliminating symptoms assocd. with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.

IT 96187-53-0, Brequinar

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(pyrimidine-based nucleoside for treatment of mitochondrial disorder)

RN. 96187-53-0 CA

CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl- (9CI) (CA INDEX NAME)



IT 96187-53-0, Brequinar

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(pyrimidine-based nucleoside for treatment of mitochondrial disorder)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

10/089,553

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT